Analyst Ratings For bluebird bio (NASDAQ:BLUE)
Today, Morgan Stanley raised its price target on bluebird bio (NASDAQ:BLUE) to $209.00 per share.
Some recent analyst ratings include
- 3/16/2018-William Blair Reiterated Rating of Buy.
- 3/14/2018-Janney Montgomery Scott initiated coverage with a Neutral rating.
- 3/13/2018-Canaccord Genuity Reiterated Rating of Buy.
- 2/22/2018-Maxim Group Reiterated Rating of Hold.
- On 3/15/2018 Mark Vachon, Director, sold 6,000 with an average share price of $214.38 per share and the total transaction amounting to $1,286,280.00.
- On 3/1/2018 Philip D Gregory, Insider, sold 2,250 with an average share price of $200.00 per share and the total transaction amounting to $450,000.00.
- On 2/2/2018 David Davidson, Insider, sold 4,000 with an average share price of $202.36 per share and the total transaction amounting to $809,440.00.
- On 1/30/2018 Jason Cole, Insider, sold 25,000 with an average share price of $195.91 per share and the total transaction amounting to $4,897,750.00.
- On 1/30/2018 Susanna Gatti High, COO, sold 17,262 with an average share price of $195.91 per share and the total transaction amounting to $3,381,798.42.
- On 1/8/2018 David Davidson, Insider, sold 3,522 with an average share price of $173.61 per share and the total transaction amounting to $611,454.42.
- On 1/5/2018 Jason Cole, Insider, sold 1,129 with an average share price of $173.38 per share and the total transaction amounting to $195,746.02.
Recent Trading Activity for bluebird bio (NASDAQ:BLUE)
Shares of bluebird bio closed the previous trading session at with 195138 shares trading hands.